Columbia-Suicide Severity Rating Scale (C-SSRS)
Also known as: C-SSRS, Columbia Suicide Severity Rating Scale
The Columbia-Suicide Severity Rating Scale is a brief clinician-administered assessment of suicide risk developed by Kelly Posner and colleagues at Columbia University to address limitations in prior screening tools. First published in the American Journal of Psychiatry in 2011, the C-SSRS has become the FDA-endorsed standard for monitoring suicidal ideation and behavior in antidepressant, anticonvulsant, and neuropsychiatric medication trials. The scale assesses both suicidal ideation (frequency and intensity) and suicidal behavior (attempts, preparatory acts) over defined time windows, providing structured risk stratification.
Key highlights
- FDA-endorsed standard—used in regulatory trials and FDA submissions; considered the reference standard for antidepressant-related suicidality monitoring
- Clear ideation-to-behavior hierarchy—distinguishes passive death wishes from active intent and planning, capturing the natural progression of suicide risk
- Excellent psychometric properties—good inter-rater reliability (ICC 0.76–0.92), test-retest reliability (kappa 0.59–0.98 by item), sensitivity and specificity both >80% for recent suicidal behavior in various populations
- Free public domain—freely available in multiple languages and formats without licensing restrictions
- Lifetime and interval versions—baseline version assesses historical risk; since-last-visit version tracks recent change, suitable for repeated monitoring
- Validated in diverse populations—demonstrated reliability across adolescents (age 12+), adults, psychiatric patients, medical patients, emergency department settings, and multiple cultural contexts
Intuition
This section is available to Pro members. Upgrade to Pro
How it works
This section is available to Pro members. Upgrade to Pro
When to use it
Recommended for: baseline suicide risk assessment at psychiatric intake or crisis evaluation; routine monitoring during antidepressant, anticonvulsant, or atypical antipsychotic trials (FDA-required in many trials); emergency department and inpatient psychiatric evaluation; ongoing outpatient follow-up for high-risk patients; research studies assessing suicide outcomes. The C-SSRS is appropriate whenever structured, standardized suicide risk assessment is needed and trained clinicians are available. Not suitable for self-screening in general medical populations without clinical follow-up; best used as part of comprehensive psychiatric evaluation.
Strengths & limitations
- FDA-endorsed standard—used in regulatory trials and FDA submissions; considered the reference standard for antidepressant-related suicidality monitoring
- Clear ideation-to-behavior hierarchy—distinguishes passive death wishes from active intent and planning, capturing the natural progression of suicide risk
- Excellent psychometric properties—good inter-rater reliability (ICC 0.76–0.92), test-retest reliability (kappa 0.59–0.98 by item), sensitivity and specificity both >80% for recent suicidal behavior in various populations
- Free public domain—freely available in multiple languages and formats without licensing restrictions
- Lifetime and interval versions—baseline version assesses historical risk; since-last-visit version tracks recent change, suitable for repeated monitoring
- Validated in diverse populations—demonstrated reliability across adolescents (age 12+), adults, psychiatric patients, medical patients, emergency department settings, and multiple cultural contexts
- Requires clinician training—semi-structured interview demands skill in probing for suicidal thoughts; untrained clinicians may miss important risk cues or incorrectly rate severity
- No single numerical score—unlike depression scales, C-SSRS results are categorical; some clinicians and systems prefer a composite risk score for documentation and communication
- Dependent on patient disclosure—patient denial or minimization of suicidal thoughts (common in acute ideation or planning) reduces sensitivity; observer verification and collateral history improve accuracy
- Limited predictive validity in general populations—the C-SSRS identifies current ideation and recent behavior well but does not reliably predict future suicide risk in community samples; high sensitivity trades for lower specificity
- Behavioral assessment relies on patient report—preparatory acts and attempts may not be fully disclosed; independent verification (ED records, call to emergency services) may be necessary
- Does not assess protective factors—the C-SSRS focuses on risk, not buffers (social support, reasons for living, coping); comprehensive risk assessment requires additional items
Common pitfalls
This section is available to Pro members. Upgrade to Pro
Applications
This section is available to Pro members. Upgrade to Pro
Frequently asked
What is the difference between ideation and behavior on the C-SSRS?
Ideation is thoughts about wanting to die or harm self (e.g., 'I wish I were dead' or 'I have thought of ways to kill myself'). Behavior is actual action: a suicide attempt, an interrupted attempt (started but stopped), an aborted attempt (prepared but did not start), or preparatory acts (acquiring means). Both ideation and behavior increase risk, but recent behavior is especially concerning.
How do I distinguish C-SSRS levels 3, 4, and 5 ideation?
Level 3: passive method ideation ('if I had a gun, I could kill myself'). Level 4: ideation with intent ('I'm having thoughts of killing myself, and I intend to do it'). Level 5: ideation with plan and intent ('I plan to overdose on pills at home tomorrow night'). Progression from 3 to 4/5 signals escalating risk; level 5 with available means is high-priority emergency.
Is the C-SSRS alone sufficient for suicide risk assessment?
No. The C-SSRS comprehensively assesses ideation and recent behavior but does not evaluate protective factors, access to lethal means, psychiatric diagnosis, substance use, or psychosocial stressors. Use the C-SSRS alongside clinical interview, risk factor assessment (prior attempts, psychiatric history, access to means), and protective factors to formulate overall risk and safety plan.
How often should I administer C-SSRS during antidepressant treatment?
FDA-recommended monitoring in trials: baseline, weeks 1, 2, 4, 8, 12, and end-of-treatment. In routine clinical care, frequency depends on risk level: high-risk patients weekly or at each visit; moderate-risk every 2–4 weeks; lower-risk annually or during medication changes. More frequent monitoring early in treatment (weeks 1–8) is prudent given FDA black-box warning.
What should I do if a patient discloses high-risk ideation with intent and specific plan?
This is a psychiatric emergency. Immediately: (1) assess access to means; (2) ensure safety (hospitalization if imminent risk); (3) notify psychiatry/crisis team; (4) do not leave patient alone; (5) document the assessment, risk level, and safety plan thoroughly; (6) follow facility protocols for high-risk patients. Safety planning and crisis communication take priority over continuing the routine visit.
Sources
- 1.Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., & Shen, S. (2011). The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. American Journal of Psychiatry, 168(12), 1266–1277.
- 2.Mundt, J. C., Greist, J. H., Jefferson, J. W., Federico, M., Mann, J. J., & Posner, K. (2013). Prediction of suicidal behavior in clinical trials of treatment for depression. Depression and Anxiety, 30(1), 22–29.
- 3.Stanley, B., & Brown, G. K. (2012). Safety planning intervention: a brief intervention to mitigate suicide risk. Cognitive and Behavioral Practice, 19(2), 256–264.
You have read it. What now?
Cite this page
ScholarGate. (2026, June 3). Columbia Suicide Severity Rating Scale. ScholarGate. https://scholargate.app/clinical-psychology/columbia-suicide-severity-rating